BTOG 2023 | Turning genomic advances into treatment options

James Spicer, FCRP, PhD, MRCP, MBBS, King’s College London, London, UK, highlights the research being undertaken into the use of existing precision medications for the treatment of lung tumors with less-familiar molecular profiles. Presently, the more accessible and detailed molecular profiling services have enabled the discernment of rarer tumor sub-types, yet many don’t have approved drugs for their treatment. The DETERMINE trial (NCT05722886), an umbrella-basket platform trial, is one such study which aims to record observations from the use of existing targeted therapies in such populations. This interview took place at the British Thoracic Oncology Group (BTOG) Annual Conference 2023 in Belfast, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.